APP substrate is labeled with both biotin and Eu3+ Cryptate and used to monitor human beta-secretase (BACE1) activity.
Feature | Specification |
---|---|
Application | Protein Quantification |
APP substrate is labeled with both biotin and Eu3+ Cryptate and used to monitor human beta-secretase (BACE1) activity.
Beta-secretase (BACE1) is an enzyme which cleaves amyloid precursor protein (APP) to produce the amyloid ß42 peptide, responsible for insoluble amyloid plaques in Alzheimer's disease (AD).
HTRF APP substrate labeled with both biotin and Eu3+ Cryptate, used with HTRF SA-XL665 or Sa-d2, provides a sensitive and efficient method for screening BACE1 inhibitors with the robustness of HTRF technology.
Application |
Protein Quantification
|
---|---|
Brand |
HTRF
|
Detection Modality |
HTRF
|
Product Group |
Fluorescent Reagent
|
Shipping Conditions |
Shipped in Dry Ice
|
Target Class |
Biomarkers
|
Target Species |
Human
|
Technology |
TR-FRET
|
Unit Size |
5,000 assay points
|
The HTRF BACE1 assay is based on our amyloid precursor protein (APP) substrate, labeled with both biotin and Eu3+ Cryptate. Active BACE1 enzyme cleaves the substrate, causing the loss of energy transfer, and thus a reduction in SA-XL665 or Sa-d2 emissions.
The assay is run in a two-step process: 1.BACE1 enzymatic reaction: Mix together the APP substrate, BACE1 and/or compounds, then incubate (we recommend a time course study to determine the optimal stimulation time). 2.BACE1 activity detection: Add Streptavidin-XL665 or Streptavidin-d2.
The HTRF BACE1 assay was used to compare the activity of soluble proBACE1 (sproBACE1) and a soluble BACE1 that was autoprocessed to remove the prodomain sequence (sautoBACe1), in the presence of selected inhibitors. 25 nM Biotin-APP substrate-Eu cryptate, 5 µM unlabeled APP peptide substrates and 6 nM enzyme were incubated for 3 h at 30 °C, pH 5.0, in the presence and absence of increasing concentrations of peptidic inhibitors.
IC50s included in Table below and are in good agreement with those reported in the literature using kinetic assays (Kennedy ME et al, Anal Biochem, 2003 Aug 1;319(1):49-55.). sproBACE1 (¦) and sautoBACE1 (°) KTEEISEVNL-(statine)-VAEF (- - - - -) EVNL(GHET)AAEF (—) ELDL(GHET)AVEF
Peptide inhibitor | IC50 for sproBACE1 (nM) | IC50 for sautoBACE1 (nM) |
---|---|---|
KTEEISEVN-(statine)-VAEF | 92 ± 9 | 82 ± 18 |
EVNL(?HET)AAEF | 8 ± 3 | 6 ± 2 |
ELDL(?HET)AVEF | 4 ± 1 | 4 ± 1 |
IsoValeryl-VV-statine-A-statine | n.d | n.d |
Are you looking for resources, click on the resource type to explore further.
Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...
This guide provides you an overview of HTRF applications in several therapeutic areas.
We are here to answer your questions.